Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Diabetes Metab Syndr. 2021 May-Jun;15(3):747-751. doi: 10.1016/j.dsx.2021.03.028. Epub 2021 Mar 29.
To determine the efficacy of i-Port Advance system on patients satisfaction and glycemic control among patients with type 1 diabetes (T1D).
This prospective study was performed among 73 patients with T1D (13-29 years) at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. Demographic data were collected at baseline and clinical characteristics were collected at baseline and 12 weeks. Patients' responses to Morisky Medication Adherence Scale (MMAS-8) and Insulin Delivery Satisfaction Survey (IDSS) were recorded at baseline and 12 weeks after initiating the i-Port Advance system.
At 12 weeks, significant improvement was evident in the IDSS subscales, which comprises the IDSS effective (p = 0.048), burdensome (p = 0.032), and IDSS inconvenient (p = 0.001), with the total baseline IDSS score being 2.6 ± 0.42, and at 12 weeks being 3.7 ± 0.72 (p = 0.037). The MMAS total score at baseline was 4.6 ± 1.2, and at 12 weeks, it increased to 6.4 (p = 0.028). HbA1c level was 8.4% at baseline and decreased to 7.9% (p = 0.001) at 12 weeks. The total daily dose of insulin at baseline registered 0.9 ± 0.13, which declined to 0.8 ± 0.12 (p = 0.048) at 12 weeks. Fasting blood sugar value was 197 ± 23.4 at baseline, which dropped to 182 ± 24.5 at 12 weeks (p = 0.01); and the postprandial glucose at baseline was 195 ± 21.4 and declined to 177 ± 19.2 at 12 weeks (p = 0.01). The hypoglycemic episodes revealed a noteworthy reduction after the i-Port Advance system usage.
Use of i-Port Advance system was found to raise the patients' satisfaction levels and lower both the hypoglycemic episodes as well as the HbA1c levels.
评估 i-Port Advance 系统在 1 型糖尿病（T1D）患者中的满意度和血糖控制效果。
本前瞻性研究在沙特阿拉伯利雅得的苏丹亲王军事医学城对 73 名 T1D 患者（13-29 岁）进行。在基线时收集人口统计学数据，并在基线和 12 周时收集临床特征。在开始使用 i-Port Advance 系统后，分别在基线和 12 周时记录患者对 Morisky 用药依从性量表（MMAS-8）和胰岛素输送满意度量表（IDSS）的应答情况。
在 12 周时，IDSS 各分量表均有显著改善，包括 IDSS 有效（p=0.048）、负担（p=0.032）和 IDSS 不便（p=0.001），基线 IDSS 总分为 2.6±0.42，12 周时为 3.7±0.72（p=0.037）。基线时 MMAS 总分为 4.6±1.2，12 周时增加到 6.4（p=0.028）。HbA1c 水平从基线时的 8.4%下降到 12 周时的 7.9%（p=0.001）。基线时胰岛素的日总剂量为 0.9±0.13，12 周时降至 0.8±0.12（p=0.048）。空腹血糖值从基线时的 197±23.4 降至 12 周时的 182±24.5（p=0.01），餐后血糖值从基线时的 195±21.4 降至 12 周时的 177±19.2（p=0.01）。使用 i-Port Advance 系统后，低血糖发作明显减少。
使用 i-Port Advance 系统可提高患者满意度，降低低血糖发作和 HbA1c 水平。
